140 related articles for article (PubMed ID: 31900594)
1. Early response monitoring of neoadjuvant chemotherapy using [
Lee I; Byun BH; Lim I; Kim BI; Choi CW; Koh JS; Song WS; Cho WH; Kong CB; Lim SM
EJNMMI Res; 2020 Jan; 10(1):1. PubMed ID: 31900594
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 99mTc-methyl diphosphonate bone scintigraphy and 18F-fluorodeoxyglucose positron emission tomography/computed tomography to predict histologic response to neoadjuvant chemotherapy in patients with osteosarcoma.
Lee I; Byun BH; Lim I; Kim BI; Kong CB; Song WS; Cho WH; Koh JS; Lim SM
Medicine (Baltimore); 2018 Sep; 97(37):e12318. PubMed ID: 30212975
[TBL] [Abstract][Full Text] [Related]
3. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
[TBL] [Abstract][Full Text] [Related]
4. [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults.
Hawkins DS; Conrad EU; Butrynski JE; Schuetze SM; Eary JF
Cancer; 2009 Aug; 115(15):3519-25. PubMed ID: 19517457
[TBL] [Abstract][Full Text] [Related]
5. Can pretreatment
Song H; Jiao Y; Wei W; Ren X; Shen C; Qiu Z; Yang Q; Wang Q; Luo QY
Eur Radiol; 2019 Jul; 29(7):3945-3954. PubMed ID: 30859285
[TBL] [Abstract][Full Text] [Related]
6. Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential ¹⁸F-FDG PET/CT and MRI.
Byun BH; Kong CB; Lim I; Kim BI; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1553-62. PubMed ID: 24652233
[TBL] [Abstract][Full Text] [Related]
7. Initial metabolic tumor volume measured by 18F-FDG PET/CT can predict the outcome of osteosarcoma of the extremities.
Byun BH; Kong CB; Park J; Seo Y; Lim I; Choi CW; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
J Nucl Med; 2013 Oct; 54(10):1725-32. PubMed ID: 23949909
[TBL] [Abstract][Full Text] [Related]
8. ¹⁸F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma.
Kong CB; Byun BH; Lim I; Choi CW; Lim SM; Song WS; Cho WH; Jeon DG; Koh JS; Yoo JY; Lee SY
Eur J Nucl Med Mol Imaging; 2013 May; 40(5):728-36. PubMed ID: 23361860
[TBL] [Abstract][Full Text] [Related]
9. Prediction of response to neoadjuvant chemotherapy in osteosarcoma using dual-phase (18)F-FDG PET/CT.
Byun BH; Kim SH; Lim SM; Lim I; Kong CB; Song WS; Cho WH; Jeon DG; Lee SY; Koh JS; Chung SK
Eur Radiol; 2015 Jul; 25(7):2015-24. PubMed ID: 25680716
[TBL] [Abstract][Full Text] [Related]
10. Prediction of Neoadjuvant Chemotherapy Response in Osteosarcoma Using Convolutional Neural Network of Tumor Center
Kim J; Jeong SY; Kim BC; Byun BH; Lim I; Kong CB; Song WS; Lim SM; Woo SK
Diagnostics (Basel); 2021 Oct; 11(11):. PubMed ID: 34829324
[TBL] [Abstract][Full Text] [Related]
11. Use of 18F-FDG-PET-CT for Assessment of Response to Neoadjuvant Chemotherapy in Children With Wilms Tumor.
Qin Z; Tang Y; Wang H; Cai W; Fu H; Li J; Ma C
J Pediatr Hematol Oncol; 2015 Jul; 37(5):396-401. PubMed ID: 25749587
[TBL] [Abstract][Full Text] [Related]
12. The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas.
Palmerini E; Colangeli M; Nanni C; Fanti S; Marchesi E; Paioli A; Picci P; Cambioli S; Donati D; Cevolani L; De Paolis M; Gambarotti M; Ferrari S
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):215-223. PubMed ID: 27645694
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer.
Champion L; Lerebours F; Alberini JL; Fourme E; Gontier E; Bertrand F; Wartski M
J Nucl Med; 2015 Sep; 56(9):1315-21. PubMed ID: 26159587
[TBL] [Abstract][Full Text] [Related]
14. Elevated tumor-to-liver uptake ratio (TLR) from
Huang J; Huang L; Zhou J; Duan Y; Zhang Z; Wang X; Huang P; Tan S; Hu P; Wang J; Huang M
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1958-1968. PubMed ID: 28812134
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model.
Dutour A; Decouvelaere AV; Monteil J; Duclos ME; Roualdes O; Rousseau R; Marec-Bérard P
J Nucl Med; 2009 Sep; 50(9):1533-40. PubMed ID: 19690032
[TBL] [Abstract][Full Text] [Related]
16. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of increased 18F-FDG uptake for detecting local recurrence in patients with extremity osteosarcoma treated with surgical resection and endoprosthetic replacement.
Chang KJ; Kong CB; Cho WH; Jeon DG; Lee SY; Lim I; Lim SM
Skeletal Radiol; 2015 Apr; 44(4):529-37. PubMed ID: 25431093
[TBL] [Abstract][Full Text] [Related]
18. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI.
Cheon GJ; Kim MS; Lee JA; Lee SY; Cho WH; Song WS; Koh JS; Yoo JY; Oh DH; Shin DS; Jeon DG
J Nucl Med; 2009 Sep; 50(9):1435-40. PubMed ID: 19690035
[TBL] [Abstract][Full Text] [Related]
19. ¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.
Groheux D; Biard L; Giacchetti S; Teixeira L; Hindié E; Cuvier C; Vercellino L; Merlet P; de Roquancourt A; de Cremoux P; Resche-Rigon M; Espié M
J Nucl Med; 2016 Apr; 57(4):536-43. PubMed ID: 26697967
[TBL] [Abstract][Full Text] [Related]
20. Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using 18F-FDG PET/CT.
Ueda S; Yoshizawa N; Shigekawa T; Takeuchi H; Ogura H; Osaki A; Saeki T; Ueda Y; Yamane T; Kuji I; Sakahara H
J Nucl Med; 2016 Aug; 57(8):1189-95. PubMed ID: 26940765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
